Education
About Us
Working with TipRanks
Follow Us
Immucell Corp. (ICCC)
NASDAQ:ICCC
ICCC Stock Chart & Stats
$6.24
-$0.45(-8.32%)
At close: 4:00 PM EST
$6.24
-$0.45(-8.32%)
Day’s Range― - ―
52-Week Range$4.52 - $7.60
Previous CloseN/A
Volume9.49K
Average Volume (3M)20.75K
Market Cap
$54.91M
Enterprise Value$51.10M
Total Cash (Recent Filing)$3.81M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding9,045,851
10 Day Avg. Volume22,482
30 Day Avg. Volume20,748
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)0.00
Price to Sales (P/S)2.01
P/FCF Ratio0.00
Enterprise Value/Market Cap0.93
Enterprise Value/Revenue1.85
Enterprise Value/Gross Profit4.46
Enterprise Value/Ebitda10.79
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Margin Expansion & Operating TurnaroundGross margin recovery to ~41% and an operating-income turnaround to $1.6M reflect durable improvements in manufacturing efficiency, pricing and cost control. Sustained higher margins support cash generation potential and create buffer to invest in commercialization and scale over the coming 2–6 months.
Manufacturing Capacity ExpansionExpanded manufacturing from ~3.0M (2023) to ~4.6M (2025) and a clear plan to reach 5–6M units mainly via yield/process changes strengthens the company’s ability to meet demand without heavy capital intensity. This structurally reduces unit costs and underpins medium-term revenue scalability if execution holds.
Product Differentiation And Market FocusFirst Defense’s biological differentiation (higher neutralizing antibodies, unique USDA-approved non‑vaccine positioning) and premium pricing support durable competitive advantage. Combined with focused commercial hires and TAM estimates (U.S. >$200M; international materially larger), this underpins longer-term pricing power and adoption.
Bears Say
Weak And Inconsistent Cash GenerationReported $0 operating and free cash flow in 2025 and historically inconsistent cash generation indicate limited internal funding capacity. With only $3.8M year‑end cash noted, the company faces constrained liquidity to fund commercialization, inventory normalization or execution shortfalls without external financing.
Revenue Volatility And Residual Profitability GapSales have been volatile (sharp swings year‑to‑year) and the company remains loss‑making at the bottom line despite operating profit. This revenue instability and lingering net loss limit predictable free cash flow and raise execution risk for sustaining investments in commercial expansion and international growth.
Impairments And Inventory Write‑downsMaterial noncash impairments and inventory write‑downs reflect prior investment missteps and asset reallocation, eroding reported equity and diluting balance‑sheet quality. While management plans to repurpose assets, these charges signal restructuring risk and highlight potential lingering operational and product transition costs.
Immucell News
ICCC FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was $4.52 and its highest was $7.60 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is $54.91M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is May 20, 2026 which is in 58 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on Mar 04, 2026. The company reported -$0.315 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.315.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,045,851 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of -$0.315 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.703%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in ICCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $64.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
29.72%
12-Months-Change
Fundamentals
Return on Equity
-4.69%
Trailing 12-Months
Asset Growth
-5.70%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
ICCC Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a broadly positive operational and strategic turnaround: revenue grew 4.3% for the year, gross margins materially improved (41% vs 30% prior year), operating income swung to $1.6M from a loss, manufacturing capacity expanded and backorders were resolved, and management has doubled down on the high-margin First Defense franchise with commercial investments underway. Notable negatives include a $2.7M Re-Tain impairment, ~$650K of inventory write-downs, a remaining net loss of $1.0M, international timing-related weakness, and execution risk associated with planned capacity/yield improvements. Overall the positives (margin expansion, operating income turnaround, strategic focus and market opportunity) outweigh the negatives, though investors should monitor execution on capacity expansion and the impact of prior write-downs.View all ICCC earnings summariesTechnical Analysis
Medicinova
―
Adicet Bio
―
Werewolf Therapeutics
―
Telomir Pharmaceuticals, Inc.
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
1.65% Insiders
3.96% Mutual Funds
3.51% Other Institutional Investors
87.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---